Gsa Capital Partners LLP Vaxcyte, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 3,584 shares of PCVX stock, worth $269,624. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,584Holding current value
$269,624% of portfolio
0.02%Shares
2 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$900 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$796 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$748 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$654 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$467 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.46B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...